Literature DB >> 894076

Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guérin.

J C Spencer, R Ganguly, R H Waldman.   

Abstract

Bacille Calmette-Guérin (BCG) has been used effectively to protect nonspecifically against bacterial infections and neoplasms, probably by enhancement of cell-mediated immunity. It has been suggested that cell-mediated immunity plays a role in the host defense against certain viral infections. In recent in vitro studies, macrophages from animals sensitized by BCG were more effective in lowering the titer of influenza virus than were macrophages from control animals. The purpose of this study was to investigate the in vivo effectiveness of nonspecific immune stimulation with BCG on influenza virus infection in mice. Immunization with BCG resulted in significant protection of mice. Also, the local (nasal) route of immunization was more effective than the systemic (intraperitoneal) route against the intranasal inoculum of virus, a finding which suggests that important role of local immunity, i.e., either earlier stimulation of secretory antibody or nonspecific cell-mediated immunity. The time course of the resistance ot infection suggests that interferon was not the protective mechanism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 894076     DOI: 10.1093/infdis/136.2.171

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

1.  Induction of enhanced resistance against encephalomyocarditis virus infection of mice by nonviable Mycobacterium tuberculosis: mechanisms of protection.

Authors:  D L Lodmell; L C Ewalt
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

Review 2.  Effects of immunopotentiating agents on alveolar macrophage properties.

Authors:  B Charley
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1986       Impact factor: 2.268

3.  Commensal bacteria calibrate the activation threshold of innate antiviral immunity.

Authors:  Michael C Abt; Lisa C Osborne; Laurel A Monticelli; Travis A Doering; Theresa Alenghat; Gregory F Sonnenberg; Michael A Paley; Marcelo Antenus; Katie L Williams; Jan Erikson; E John Wherry; David Artis
Journal:  Immunity       Date:  2012-06-14       Impact factor: 31.745

Review 4.  Postinfectious Epigenetic Immune Modifications - A Double-Edged Sword.

Authors:  Andrew R DiNardo; Mihai G Netea; Daniel M Musher
Journal:  N Engl J Med       Date:  2021-01-21       Impact factor: 91.245

Review 5.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Enhancement of bronchoalveolar cell recovery and stimulation of alveolar macrophage chemiluminescence and resistance to influenza virus after treatment with RU 41821 aerosol.

Authors:  A Rudent; F Michel; C Labarre; A M Quero; R Zalisz; P Smets
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

7.  Glucan-induced enhancement of host resistance to selected infectious diseases.

Authors:  J A Reynolds; M D Kastello; D G Harrington; C L Crabbs; C J Peters; J V Jemski; G H Scott; N R Di Luzio
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

8.  Enhancement of natural resistance to influenza virus in lipopolysaccharide-responsive and -nonresponsive mice by Propionibacterium acnes.

Authors:  J D Gangemi; J A Hightower; R A Jackson; M H Maher; M G Welsh; M M Sigel
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

9.  Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients.

Authors:  H G Stiver; B H Weinerman
Journal:  Can Med Assoc J       Date:  1978-10-07       Impact factor: 8.262

10.  Appearance of rosette-forming macrophages in the lungs of influenza virus-infected mice.

Authors:  P R Wyde; T R Cate
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.